Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Fineline Cube May 7, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Drug

Yantai Dongcheng Pharmaceutical Gets NMPA Green Light for FAP-Targeting Radiotherapeutic Drug

Fineline Cube Dec 5, 2023

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has received approval...

Company Drug

Tonghua Dongbao Pharmaceuticals Secures NMPA Approval for Biosimilar Liraglutide

Fineline Cube Dec 5, 2023

Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced that it has received...

Company Drug

Simcere Pharmaceutical’s SIM0501 Receives FDA Approval for Advanced Solid Tumor Clinical Trial

Fineline Cube Dec 5, 2023

Simcere Pharmaceutical Group (HKG: 2096) has announced that it has received clinical trial approval from...

Company

WuXi Biologics Shares Plunge 22% on Slower CDMO Industry Growth and Revenue Shortfall

Fineline Cube Dec 5, 2023

WuXi Biologics (HKG: 2269) experienced a 22% decline in its share price on Monday, December...

Company Deals

Abbisko Therapeutics Strikes Licensing Deal with Merck KGaA for CSF-1R Inhibitor Pimicotinib

Fineline Cube Dec 5, 2023

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced a licensing agreement...

Company Deals

Boehringer Ingelheim Partners with Shanghai Handu Pharma to Enhance Oral Medication Delivery

Fineline Cube Dec 5, 2023

Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Shanghai Handu...

Company Deals

Gedeon Richter Acquires Rights to Mithra’s Contraceptive and Menopause Treatments for Chinese Market

Fineline Cube Dec 5, 2023

Gedeon Richter Plc, a Hungarian pharmaceutical company, and Belgium’s Mithra (OTCMKTS: MITPF) have entered into...

Company Deals

Aspen Pharmacare Holdings to Boost China Presence with Full Acquisition of Sandoz’s Subsidiary

Fineline Cube Dec 5, 2023

Aspen Pharmacare Holdings (JSE: APN), a South Africa-based pharmaceutical company, is poised to enhance its...

Company Drug

AstraZeneca Halts Late-Stage Trials for Lokelma in Hyperkalemia Due to Timing and Event Rate Issues

Fineline Cube Dec 5, 2023

AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, has announced the termination of two...

Company Deals

Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition

Fineline Cube Dec 5, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has entered into an agreement to acquire U.S. biotech...

Company Drug

Stem-Cell Startup Xellsmart Earns FDA Orphan Drug Designation for ALS Therapy

Fineline Cube Dec 5, 2023

Xellsmart, a stem-cell startup headquartered in Suzhou, has announced that it has received orphan drug...

Company Drug

Worg Pharmaceuticals Gets FDA Approval for Phase II Graves’ Disease Study

Fineline Cube Dec 5, 2023

Worg Pharmaceuticals, a Hangzhou-based developer of allergic drugs, has received the green light from the...

Company Drug

Nanchang Baiji Pharmaceutical’s Budesonide Nasal Spray Approved by China’s NMPA

Fineline Cube Dec 5, 2023

Nanchang Baiji Pharmaceutical Co. Ltd., a Chinese pharmaceutical company, has received approval from the National...

Company Drug

Eli Lilly’s Jaypirca Receives FDA Accelerated Approval for Chronic Lymphocytic Leukemia

Fineline Cube Dec 5, 2023

The US Food and Drug Administration (FDA) has granted Eli Lilly (NYSE: LLY) an accelerated...

Company Deals

Autobio Diagnostics and China National Medical Device Form Strategic Partnership

Fineline Cube Dec 5, 2023

Autobio Diagnostics Co., Ltd (SHA: 603658), a Chinese in-vitro diagnostics company, has entered into a...

Company Medical Device

Valgen Secures NMPA Approval for China’s First Transcatheter Mitral Valve Clamp System

Fineline Cube Dec 4, 2023

Hangzhou-based Valgen Holding Corporation has received market approval from the National Medical Products Administration (NMPA)...

Company Drug

Ambio Gains FDA Approval for Generic Forteo, Challenging Eli Lilly’s Osteoporosis Market

Fineline Cube Dec 4, 2023

Ambio has secured regulatory approval from the U.S. Food and Drug Administration (FDA) for its...

Company Drug

Chinese Firms Secure EUAs for Omicron XBB Vaccines Amid Dominant Variant Surge

Fineline Cube Dec 4, 2023

A wave of Chinese pharmaceutical companies has announced the receipt of Emergency Use Authorizations (EUAs)...

Company Drug

Pfizer’s Danuglipron Phase IIb Trial Achieves Weight Loss Goals Amid Tolerability Concerns

Fineline Cube Dec 4, 2023

Pfizer (NYSE: PFE) announced last week that its Phase IIb trial evaluating danuglipron, a glucagon-like...

Company Drug

Everest Medicines Secures IND Review for Zetomipzomib in China

Fineline Cube Dec 4, 2023

Everest Medicines (HKG: 1952) has announced that its Investigational New Drug (IND) application for zetomipzomib...

Posts pagination

1 … 429 430 431 … 661

Recent updates

  • Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
  • GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
  • Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%
  • Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion
  • China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Company

GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook

Company

Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%

Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.